drugset

drugset / Trial / NCT00102492

Study Of GW679769 In Major Depressive Disorder

NCT00102492 ↗

Phase 2 Completed 356 enrolled GlaxoSmithKline

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.

Timeline

Start: 2004-10
Primary completion: 2006-09
Completion: 2006-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Casopitant	Small molecule	—	—

Indications